Annals of Nutrition and Metabolism
Original Paper
Ameliorative Effects of Stabilized Rice Bran on Type 2 Diabetes PatientsCheng H.-H.a · Huang H.-Y.a · Chen Y.-Y.a · Huang C.-L.b · Chang C.-J.c · Chen H.-L.d · Lai M.-H.eaSchool of Nutrition and Health Science, Taipei Medical University, bDepartment of Internal Medicine, Taipei Medical University Hospital, cDivision of Endocrinology and Metabolism, Department of Internal Medicine, Taipei Medical University-Municipal Wan Fang Hospital, Taipei, dDivision of Endocrinology and Metabolism, Lotung Poh-Ai Hospital, Yilan, and eDepartment of Nursing, Cardinal Tien College of Healthcare and Management, Kainan University, Taipei, Taiwan, ROC
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: October 07, 2008
Accepted: October 14, 2009
Published online: December 15, 2009
Issue release date: February 2010
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 5
ISSN: 0250-6807 (Print)
eISSN: 1421-9697 (Online)
For additional information: https://www.karger.com/ANM
Abstract
Background/Aim: While it has been demonstrated that rice bran might lower the cholesterol level in hypercholesterolemic individuals, its effects on the levels of adiponectin and glycated hemoglobin (HbA1c) in patients with type 2 diabetes mellitus remain unknown. Methods: Twenty-eight volunteers with type 2 diabetes were randomly divided into 2 groups, one of which received a dietary supplement of 20 g of stabilized rice bran and the other placebo once daily for 12 weeks. Parameters such as the level of HbA1c, glucose, insulin, homeostasis model assessment for estimation of relative insulin resistance, high-density and low-density lipoprotein (LDL) cholesterol and adiponectin were evaluated. Results: At the end of the study period, postprandial glucose and the area under the glucose curve of the rice bran group were significantly lower than baseline levels by 14.4 and 15.7%, respectively. Compared to baseline, the HbA1c values in the rice bran group were also significantly lower. Serum total cholesterol and LDL cholesterol concentrations in the rice bran group were 9.2 and 13.7% lower, respectively, than in the placebo group. The plasma free fatty acid and adiponectin concentrations were 20% lower and 40% higher in the rice bran group compared to the placebo group. Conclusions: This study demonstrated that stabilized rice bran can lower the level of HbA1c and blood lipids and increase blood adiponectin concentrations in type 2 diabetic subjects. In light of this, we conclude that stabilized rice bran may represent an important functional nutrient to ameliorate lipid and glycemic anomalies in type 2 diabetic subjects.
© 2009 S. Karger AG, Basel
Related Articles:
References
-
US Department of Health and Human Services, US Department of Agriculture: Dietary Guidelines for Americans. Washington, US Government Printing Office, 2005.
- Meyer KA, Kushi LH, Jacobs DR Jr, Slavin J, Sellers TA, Folsom AR: Carbohydrates, dietary fiber, and incident type 2 diabetes in older women. Am J Clin Nutr 2000;71:921–930.
- Liu S, Manson JE, Stampfer MJ, Rexrode KM, Hu FB, Rimm EB, Willett WC: Whole grain consumption and risk of ischemic stroke in women: a prospective study. JAMA 2000;284:1534–1540.
-
Hegsted M, Windhauser MM, Morris SK, Lester SB: Stabilized rice bran and oat bran lower cholesterol in humans. Nutr Res 1993;13:387–398.
External Resources
- Cara L, Dubois C, Borel P, Armand M, Senft M, Portugal H, Pauli AM, Bernard PM, Lairon D: Effects of oat bran, rice bran, wheat fiber, and wheat germ on postprandial lipemia in healthy adults. Am J Clin Nutr 1992;55:81–88.
- Gerhardt AL, Gallo NB: Full-fat rice bran and oat bran similarly reduce hypercholesterolemia in humans. J Nutr 1998;128:865–869.
- Weyer C, Tataranni PA, Bogardus C, Pratley RE: Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 2001;24:89–94.
- Droumaguet C, Balkau B, Simon D, Caces E, Tichet J, Charles MA, Eschwege E: Use of HbA1c in predicting progression to diabetes in French men and women: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2006;29:1619–1625.
- Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tatranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930–1935.
- Groop LC, Bonadonna RC, Del Prato S, Ratheiser K, Zyck K, DeFronzo RA: Effect of insulin on oxidative and non-oxidative pathways of glucose and FFA metabolism in NIDDM. Evidence for multiple sites of insulin resistance. J Clin Invest 1989;84:205–213.
- Boden G, Shulman GI: Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β cell dysfunction. Eur J Clin Invest 2002;32(suppl 3):14–23.
- McGarry JD: Banting Lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002;51:7–18.
-
Kashyap S, Belfort R, Pratipanawatr T, Berria R, Pratipanawatr W, Bajaj M, Mandarino L, DeFronzo R: Chronic elevation in plasma free fatty acids impairs insulin secretion in non-diabetic offspring with a strong family history of T2DM. Diabetes 2002;51(suppl 2):A12.
- Qureshi AA, Mo H, Packer L, Peterson DM: Isolation and identification of novel tocotrienols from rice bran with hypocholesterolemic, antioxidant, and antitumor properties. J Agric Food Chem 2000;48:3130–3140.
-
Association of Official Analytical Chemists: Official Methods of Analysis, ed 13. Washington, Association of Official Analytical Chemists, 1980.
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.
- Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
- Monnier L, Colette C, Thuan JF, Lapinski H: Insulin secretion and sensitivity as determinants of HbA1c in type 2 diabetes. Eur J Clin Invest 2006;36:231–235.
- Pratley RE, Weyer C: The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 2001;44:929–945.
- Potter JG, Coffman KP, Reid RL, Krall JM, Albrink MJ: Effect of test meals of varying dietary fiber content on plasma insulin and glucose response. Am J Clin Nutr 1981;34:328–334.
- Jenkins DJ, Jenkins AL: Dietary fiber and the glycemic response. Proc Soc Exp Biol Med 1985;180:422–431.
- Jung EH, Kim SR, Hwang IK, Ha TY: Hypoglycemic effects of a phenolic acid fraction of rice bran and ferulic acid in C57BL/KsJ-db/db mice. J Agric Food Chem 2007;55:9800–9804.
- Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, Pratley RE, Bogardus C, Tataranni PA: Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002;51:1884–1888.
- Yamauchi T, Kamon J, Minokoshi Y: Adiponectin stimulates glucose utilization and fatty acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288–1295.
- Yamauchi T, Kamon J, Waki H, et al: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941–946.
- Bloomgarden ZT: Cardiovascular disease and diabetes. Diabetes Care 2003;26:230–237.
- Kerckhoffs DAJM, Brouns F, Hornstra G, Mensink RP: Effects on the human serum lipoprotein profile of β-glucan, soy protein and isoflavones, plant sterols and stanols, garlic and tocotrienols. J Nutr 2002;132:2494–2505.
-
Qureshi A, Bradlow BA, Salser WA, Brace LD: Novel tocotrienols of rice bran modulate cardiovascular disease risk parameters of hypercholesterolemic humans. J Nutr Biochem 1997;8:290–298.
External Resources
- Qureshi AA, Sami SA, Salser WA, Khan FA: Dose-dependent suppression of serum cholesterol by tocotrienol-rich fraction (TRF25) of rice bran in hypercholesterolemic humans. Atherosclerosis 2002;161:199–207.
- Sugano M, Tsuji E: Rice bran oil and cholesterol metabolism. J Nutr 1997;127:521S–524S.
- Chen CW, Cheng HH: A rice bran oil diet increases LDL-receptor and HMG-CoA reductase mRNA expressions and insulin sensitivity in rats with streptozotocin/nicotinamide-induced type 2 diabetes. J Nutr 2006;136:1472–1476.
- Most MM, Tulley R, Morales S, Lefevre M: Rice bran oil, not fiber, lowers cholesterol in humans. Am J Clin Nutr 2005;81:64–68.
- Qvigstad E, Mostad IL, Bjerve KS, Grill VE: Acute lowering of circulating fatty acids improves insulin secretion in a subset of type 2 diabetes subjects. Am J Physiol Endocrinol Metab 2003;284:E129–E137.
- Xu Z, Hua N, Godber JS: Antioxidant activity of tocopherols, tocotrienols, and gamma-oryzanol components from rice bran against cholesterol oxidation accelerated by 2,2′-azobis (2-methylpropionamidine) dihydrochloride. J Agric Food Chem 2001;49:2077–2081.
- Frank N, Andrews FM, Elliott SB, Lew J, Boston RC: Effects of rice bran oil on plasma lipid concentration, lipoprotein composition, and glucose dynamics in mares. J Anim Sci 2005;83:2509–2518.
- Cartmill JA, Thompson DL, Gentry LR, Pruett HE, Johnson CA: Effects of dexamethasone, glucose infusion, adrenocorticotropin, and propylthiouracil on plasma leptin concentrations in horses. Domest Anim Endocrinol 2003;24:1–14.
Article / Publication Details
Received: October 07, 2008
Accepted: October 14, 2009
Published online: December 15, 2009
Issue release date: February 2010
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 5
ISSN: 0250-6807 (Print)
eISSN: 1421-9697 (Online)
For additional information: https://www.karger.com/ANM
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
